C4 therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating cft1946, an orally bioavailable bidac™ degrader, in braf v600 mutant solid tumors

Watertown, mass., jan. 30, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its phase 1/2 clinical trial of cft1946, an orally bioavailable mutant-selective bidac™ degrader for the treatment of braf v600 mutant solid tumors.
CCCC Ratings Summary
CCCC Quant Ranking